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Abstract
The microtubule-associated protein tau (MAPT) is a pathological component of several
neurodegenerative diseases and clinical dementias. Here, we have investigated the effects of a
series of commercially available FDA-approved compounds and natural products on total tau
protein levels using a cell-based approach that allows for the rapid and efficient measurement of
changes in protein expression.
Results: The compounds that reduced tau largely fell within 3 functional categories with the largest
percentage being microtubule regulators. Several of these candidates were validated in both a
human neuroglioma and a human neuroblastoma cell line. While these drugs lead to a rapid
reduction in tau protein levels, a selective decrease in MAPT mRNA expression was also observed.
Conclusion: These findings suggest that the identified compounds that reduce tau levels may act
either through direct effects on the MAPT promoter itself or by altering a feedback transcriptional
mechanism regulating MAPT transcription. This is particularly interesting in light of recent evidence
suggesting that MAPT 5' UTR mutations in late-onset PD and PSP cases alter the expression of tau
mRNA. In fact, one of the compounds we identified, rotenone, has been used extensively to model
PD in rodents. These observations may provide key insights into the mechanism of tau turnover
within the neuron while also providing the first evidence that selectively reducing tau protein levels
may be possible using compounds that are FDA-approved for other uses.
Background
The microtubule-associated protein tau (MAPT) has been
demonstrated to be an integral component of axon forma-
tion and neuronal transport, and serves as a substrate for
multiple cellular signaling pathways [1,2]. However, in
several neurological disorders with clinical dementia, tau
apparently loses its normal function and begins to aber-
rantly accumulate into various types of pathological inclu-
sions. Mutations within the MAPT gene [3,4], were shown
to result in the formation of neurofibrillary tau aggregates
leading to FTDP-17 (frontotemporal dementia with par-
kinsonism linked to chromosome 17), thus providing
conclusive evidence that abnormalities in tau are suffi-
cient to produce neurodegeneration and dementia. While
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Alzheimer's disease (AD) is indeed the predominant
dementia demonstrating consistent tau pathology, the
accumulation of abnormally phosphorylated tau species
is also a primary histopathologic hallmark of several other
heritable dementias, including corticobasal degeneration
(CBD), parasupranuclear palsy (PSP) and frontotemporal
dementia (FTD). In addition, post-mortem assessments of
many late onset Parkinson's disease (PD) cases demon-
strate abnormal tau aggregation, further suggesting the
central role that this protein may have in a host of neuro-
logical disorders not associated with amyloid deposition
as with AD.
Recent evidence has indicated that the abnormal intracel-
lular accumulation of tau may ultimately be self-perpetu-
ating [5], and this conversion of tau has been proposed to
be a toxic gain-of-function phenomenon [6]. The recent
generation of viable and seemingly normal MAPT -/- mice
has raised the possibility that neurons may be tolerant of
perturbations in the overall levels of tau protein. Collec-
tively, these data suggest that reductions in tau may be a
viable therapeutic application. In further support of this
notion, Santacruz et al. also recently demonstrated that
reducing the expression of MAPT mRNA in a Tet-Off
inducible tau mouse model reversed the cognitive deficits
and neuronal loss in these mice without reducing the
number of tau aggregates [7]. Therefore, tau itself rather
than the aggregates and tangles, may serve as a valid ther-
apeutic candidate, particularly in cases caused by familial
mutations of the MAPT locus. These studies demonstrate
the need for compounds to facilitate the removal of either
the total pool of tau or specific aberrant forms of tau (i.e.
hyperphosphorylated, misfolded, etc.). Unfortunately,
however, the feasibility of large scale efforts to identify
modifiers of endogenous protein species has proven tech-
nically challenging. We recently developed a novel tech-
nique to quantitatively measure various tau species,
including an assay to analyze total tau protein while
simultaneously measuring GAPDH levels as an estimate
of cell viability [8]. Using this platform, we have screened
a library of off-patent compounds and have identified sev-
eral that are capable of reducing tau levels in brain-derived
cell lines.
Results
A primary pathological contributor to several dementias is
the abnormal accumulation of the tau protein. Therefore
reducing the overall levels of this protein may hold thera-
peutic relevance. We have developed a quantitative cell-
based screening methodology for measuring intracellular
tau protein levels to identify off-patent and FDA-approved
compounds that may hold efficacy against this major pro-
tein component of AD pathology. Preliminary Western
blot analyses revealed that, combined with their robust
adhesiveness, H4 human neuroglioma-like cells have sub-
stantial tau immunoreactivity corresponding to both 3
and 4 repeat human tau isoforms (Fig 1A). Therefore, we
chose this line for all subsequent screens to assess total tau
levels. To determine the dynamic linear range for tau and
GAPDH in the H4 cells using the In Cell Western assay,
cells were plated at different seeding densities and incu-
bated for 48 hours. We determined that for tau detection
with the 680 nm fluorescent-labeled anti-rabbit second-
ary antibody and GAPDH detection with the 800 nm flu-
orescent-labeled anti-mouse secondary antibody, the
optimal range for detecting tau was at a point when H4
cells were seeded at a density between ~3 × 104 and ~4 ×
105 per well (Fig 1C). We then determined that the coeffi-
cient of variance was 5% for total tau immunoreactivity
and the signal-to-background ratio was approximately
12.9×. We therefore seeded 8 × 104 cells/well for all subse-
quent investigations.
Using this ICW paradigm, we screened a commercially
available chemical library containing ~880 functionally
diverse molecules (85% of which are commercially mar-
keted) for compounds that reduced total tau levels. Initial
analyses revealed that 26 compounds (3 %) were shown
to significantly (p < 0.05) reduce tau immunoreactivity
(IR) relative to GAPDH IR (Table 1). Of these 26 com-
pounds, 9 resulted in >25% reduction in GAPDH IR
(Table 1; italics). Two compounds, epicatechin and beta-
methasone, were falsely identified by our initial analyses
as they increased GAPDH IR without changing tau IR
(Table 1; small caps) and this altered the tau/GAPDH
ratio used to initially identify compounds. Nine com-
pounds caused a >25% reduction in tau levels with <10%
reductions in GAPDH IR, perhaps representing the most
optimal category for therapeutic relevance (Table 1; bold).
The remaining six compounds did reduce tau by at least
19% (ciclopirox) or more, with differing effects on
GAPDH levels (Table 1; bold-italics).
To further identify optimal therapeutic candidates, we
performed a dose response on the H4 cells with the ICW
methodology (100 μM to 10 nM) along with LDH analy-
ses. Thirteen compounds were chosen from the initial 25
based on several factors including the potency of the tau
IR reductions from the primary screens, relevance from lit-
erature and commercial availability. Only 6 compounds
demonstrated a therapeutic window where the concentra-
tion that reduced tau levels by 50% was 10-fold less than
the concentration that was toxic to 50% of the cells (as
assessed by LDH levels). Five of these compounds (dau-
norubicin, methylene blue, camptothecine, paclitaxel and
albendazole; betamethasone was excluded due to
increased GAPDH IR in primary screens), were further
characterized for their effects on tau by Western blot and
qRT-PCR analyses. Western blot analysis revealed that tau
levels were significantly reduced in a dose-dependentMolecular Neurodegeneration 2006, 1:6 http://www.molecularneurodegeneration.com/content/1/1/6
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In-Cell Western Optimization Figure 1
In-Cell Western Optimization. (A) Tau levels from multiple cell lines were assessed by Western blot. H4 neuroglioma 
cells were chosen for the assay for several reasons including relatively robust tau expression, adhesion properties and human 
neural lineage. β-actin levels were assayed to control for variations in protein loading. (B) H4 cells were plated in a 96-well 
plate and tau immunoreactivity was determined by fluorescent (680 nm) secondary antibody detection using the Odyssey infra-
red scanner. Conditions were optimized to produce a low 5% well-to-well variation across the plate represented as CV (coef-
ficient of variance) for rows B-G, and a signal-to-background ratio of >10-fold (12.9; background is empty wells in rows A and 
H). (C) Cells were plated at the densities indicated on the x-axis. Relative Fluorescence for triplicate wells were averaged and 
the standard deviation was calculated. Black diamonds () indicate tau immunoreactivity with detection at 680 nm; gray boxes 
(■) indicate GAPDH immunoreactivity with detection at 800 nmMolecular Neurodegeneration 2006, 1:6 http://www.molecularneurodegeneration.com/content/1/1/6
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manner for all 5 compounds relative to vehicle treated
cells (Figure 2). Daunorubicin and camptothecine dem-
onstrated similar reductions in MAP2 levels and slight
reductions in GAPDH IR whereas paclitaxel, methylene
blue and albendazole appear to reduce tau specifically
(Figure 2). To determine the universality of these effects,
we then assessed efficacy in both the M17 and N2A cell
lines. Interestingly, only tau within the human M17 neu-
roblastoma cell line (Figure 3) was responsive to treat-
ment with the 5 lead candidates, while N2A tau levels
remained largely unchanged (not shown). Thus, these
effects were not replicated in a murine neuroblastoma cell
line, suggesting that the compounds identified may not
have sufficient efficacy in mouse model systems, despite
efficacy in two different human CNS derived cell lines.
Real time PCR was then used to determine if tau mRNA
expression in the H4 cell line was altered following treat-
ment with these 5 candidates. Interestingly, daunoru-
bicin, paclitaxel, albendazole and camptothecine all
reduced tau mRNA levels relative to GAPDH (Fig 4).
Camptothecine and paclitaxel caused dose responsive
reductions in tau mRNA whereas albendazole and dauno-
rubicin similarly reduced tau levels at each concentration
(with the exception of the 10 μM daunorubicin concentra-
tion that had no detectable mRNA expression for either
tau or GAPDH). Conversely, methylene blue increased tau
mRNA expression relative to GAPDH despite reducing tau
protein levels (Fig 4). Chelidonine was included as a con-
trol compound that reduced tau levels by primary screens
but did not change mRNA expression.
Discussion
While most recent AD therapeutic development has
focused on the removal of Aβ or prevention of its aggrega-
tion into plaques, the recent findings by Oddo et al and
Table 1: Tau-reducing compounds identified from initial in-cell western screening assay
Functional Grouping Drug Name Tau IR as a % Of Vehicle 
Control
GAPDH IR as a % Of Vehicle 
Control
Aggregation inhibitors Daunorubicin 21 ± 0 52 ± 6
Diazaquone 66 ± 3 106 ± 6
Methylene Blue 72 ± 6 112 ± 6
EPICATECHIN 100 ± 4 140 ± 5
Doxorubicin HCl 41 ± 3 56 ± 6
Antibiotics Alexidine HCl 57 ± 0 91 ± 9
Gramicidin 58 ± 0 84 ± 0
Ciclopirox  81 ± 2 109 ± 6
Anti-proliferatives Camptothecine 38 ± 0 71 ± 1
Azacytidine-5 40 ± 0 56 ± 3
Emetine diHCl 51 ± 11 69 ± 2
Mycophenolic Acid 77 ± 0 100 ± 7
Azaguanine-8 79 ± 0 88 ± 3
Microtubule regulators Paclitaxel 47 ± 2 61 ± 4
Colchicine 44 ± 0 93 ± 6
Albendazole 44 ± 4 93 ± 12
Podophyllotoxin 37 ± 0 63 ± 2
Nocodazole 38 ± 0 61 ± 3
Mebendazole 45 ± 3 69 ± 4
Fenbendazole 51 ± 2 76 ± 9
Chelidonine  67 ± 0 96 ± 4
Rotenone 72 ± 0 99 ± 1
Receptor Antagonists Lanotoside C 61 ± 2 79 ± 2
Lasalocid Na salt 77 ± 2 96 ± 2
Steroids BETAMETHASONE 99 ± 0 146 ± 13
Norethindrone 69 ± 1  110 ± 3
Italics = Drugs that reduced tau levels, but that reduced GAPDH levels by >25% indicating some toxicity; SMALL CAPS = Drugs that increased 
GAPDH levels without reducing tau levels; Bold = Drugs resulting in >25% reductions in tau levels with <10% reductions in GAPDH levels; Bold 
Italics = Drugs demonstrating <25% reductions in tau levels and/or 10–25% changes in GAPDH levels. IR indicates immunoreactivity. SD indicates 
standard deviation. Compounds are grouped based on their functional class.Molecular Neurodegeneration 2006, 1:6 http://www.molecularneurodegeneration.com/content/1/1/6
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Santacruz et al. that tau accumulation can only be
reversed at an early stage in its AD pathogenesis highlights
the need for therapeutic strategies to slow or even stop tau
accumulation in this disease and other hereditary tauopa-
thies [5,7]. Several strategies have recently been suggested
that target various pathologically associated tau species,
including hyperphosphorylated and aggregation-compe-
tent species (For review see [6]).
While the tau protein was originally characterized as a
late-stage component of AD pathology, the identification
of mutations within the MAPT gene itself in patients with
clinical dementia and a parkinsonian phenotype (i.e.
FTDP-17) [3] demonstrated that tau, in and of itself, is
capable of causing neurodegenerative disease. In fact, sev-
eral studies have now demonstrated that genetic variation
in the critical 5' and promoter region of the MAPT locus
was associated with typical late-onset PD (LOPD) [12,13]
and irregular tau accumulation has been observed in both
parkinsonism kindreds and sporadic LOPD cases [14].
Furthermore, a recent report demonstrated that tau tran-
scriptional activity was impaired by introduction of a sin-
gle nucleotide polymorphism found on the H1 haplotype
of progressive supranuclear palsy patients [15]. Thus,
altered expression of the tau protein may indeed contrib-
ute to the onset of parkinsonism, including LOPD. While
both α-synuclein and tau accumulation are often a neu-
ropathological feature of clinically diagnosed PD patients
following post-mortem examination, a recent study dem-
onstrated that adenoviral over-expression of tau, but not
α-synuclein, was sufficient to promote dopaminergic neu-
ronal loss and impair rotational behavior in otherwise
Validation of candidate compound efficacy for tau reductions  in H4 neuroglioma cells by standard Western blot Figure 2
Validation of candidate compound efficacy for tau 
reductions in H4 neuroglioma cells by standard 
Western blot. H4 neuroglioma cells were treated at 90% 
confluency for 24 hours with respective μM concentrations 
of drugs shown at the top of each lane. Cells were then har-
vested and homogenized, normalized for protein concentra-
tion and subjected to SDS-PAGE followed by probing for 
total tau, MAP2 and GAPDH. We validated the efficacy of 5 
compounds by Western blotting demonstrating that two of 
these compounds, daunorubicin and camptothecine, show 
capacity to reduce both MAPs and GAPDH compared to 
vehicle (bottom right), while the other 3 compounds, paclit-
axel, methylene blue and albendazole, all appear to have spe-
cific effects on tau levels compared to vehicle.
Validation of candidate compound efficacy for tau reductions  in M17 neuroblastoma cells by standard Western blot Figure 3
Validation of candidate compound efficacy for tau 
reductions in M17 neuroblastoma cells by standard 
Western blot. M17 neuroblastoma cells were treated at 
90% confluency for 24 hours with respective μM concentra-
tions of drugs shown at the top of each lane. Cells were then 
harvested and homogenized, normalized for protein concen-
tration and subjected to SDS-PAGE followed by probing for 
total tau and GAPDH. All 5 compounds altered tau levels. 
Several compounds caused fragmentation of tau relative to 
vehicle treated cells. Note the high molecular weight species 
present at the 1 μM dose of daunorubicin and the 1 and 0.1 
μM doses of camptothecine, perhaps indicating the formation 
of a multimeric structure during tau degradation.Molecular Neurodegeneration 2006, 1:6 http://www.molecularneurodegeneration.com/content/1/1/6
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normal rats, further supporting an important role for tau
in the pathogenesis of PD [16].
Here, based on findings that mice entirely deficient of tau
expression are quite viable [17,18] and the notion that
generally reducing the pool of tau available for further
aggregation may hold therapeutic potential after disease
onset, we analyzed a small library of predominantly mar-
keted compounds for their ability to reduce total tau pro-
tein levels. Using an ICW assay [8,9], we have
demonstrated that several compounds indeed appear able
to reduce tau protein levels, and that out of 25 com-
pounds identified, 9 were involved with microtubule
dynamics and 4 were putative protein filament/aggrega-
tion inhibitors. We demonstrated that several of these
drugs were able to selectively lower tau levels without
affecting another microtubule-associated protein, MAP2.
In addition, several (5) anti-proliferative compounds
were identified from our screens, further emphasizing the
role that tau plays in cell division and the potential sensi-
tivity of its expression based on the functional require-
ments of the cell at any given time.
We classified tau-reducing compounds based on their
functional capacity as cited in the current body of litera-
ture. Inasmuch, a recent report by Pickhardt and col-
leagues demonstrated that anthraquinones were able to
dissolve paired helical filaments of tau and inhibit its
aggregation [20]. Earlier work has also demonstrated that
doxorubicin regulates both tau metabolism [21] and dis-
rupts microtubules [22]. Therefore, our identification of
anthraquinones, such as doxorubicin and daunorubicin,
as reducers of total tau levels, is not only consistent with
previous findings, it also provides additional support for
the idea that tau levels may be highly dynamic based on
the requirement of the cell for the generation of microtu-
bule networks. Perhaps more importantly, these findings
suggest that the degradation of tau is a highly ordered
process that requires precise synchronicity at both the
translational and transcriptional levels due to the multi-
ple cleavage fragments, the reductions in MAPT mRNA
levels, and even the appearance of higher molecular
weight tau species that are produced by these compounds.
We also noticed that while toxicity was certainly observed
with several compounds, tau levels were significantly
lower compared with GAPDH levels. This was somewhat
surprising as the half-life of both tau protein and mRNA
are thought to be relatively long-lived [23,24] compared
to other molecules. Certainly, while under normal condi-
tions tau might be quite stable, our results suggest that
compounds targeting the tubulin, the substrate of tau,
promote the rapid and ordered removal of tau from the
cell. This may indicate that impaired degradation of the
tau protein could ultimately facilitate its abnormal accu-
mulation in a diseased condition such as AD and PD.
Follow-up studies in the H4 cell line revealed that a pri-
mary mechanism by which these compounds elicited tau
reductions was likely due to reduced transcriptional activ-
ity (Fig 4). Some conclusions regarding specificity of this
effect can be drawn as it has previously been demon-
strated that tau mRNA is an extremely stable transcript in
neurons due to 3' UTR structural motifs [24]. These results
perhaps indicate that the MAPT 5' UTR is being directly
modulated by these compounds, or that microtubule
destabilization activates a negative feedback pathway that
reduces tau expression. It is therefore possible that one of
the fragments produced by treatment with these com-
pounds (Fig 3) is also negatively regulating MAPT mRNA
expression. This could link the genetic association found
in the 5' MAPT locus for LOPD that seems to lead to
enhanced tau expression [Kwok] [Skipper] with a func-
tional consequence of impaired intraneuronal transport
due to microtubule breakdown and altered tau expression
(i.e. presynaptic accumulation of α-synuclein and mito-
chondrial breakdown, two classical features of PD). This
finding also supports earlier work by Litman et al., dem-
onstrating that tau mRNA itself co-localizes with intact
microtubules within axons [25], and therefore, disruption
of microtubules may lead to local reductions in both tau
protein and mRNA levels. This could also suggest that
MAPT mRNA is perhaps locally translated at the pre-syn-
apse, providing for a mechanism of rapid regulation that
is not impeded by classical protein trafficking from the
nucleus. Therefore, the alteration of microtubule stability
may in fact lead to altered expression levels of tau.
Compounds that reduce tau protein levels also affect mRNA  expression Figure 4
Compounds that reduce tau protein levels also affect 
mRNA expression. H4 cells were treated in triplicate with 
10, 1, and 0.1 μM of compounds listed on x-axis. Quantita-
tive real time PCR was used to determine expression levels 
of tau relative to GAPDH. Relative fluorescent units (RFUs) 
were determined and presented here as a percentage of the 
vehicle-treated controls. "NS" indicates no RFUs detected.Molecular Neurodegeneration 2006, 1:6 http://www.molecularneurodegeneration.com/content/1/1/6
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When human neuroblastoma cells were treated with sev-
eral of these same compounds and subjected to Western
analysis, marked degradation of tau was observed and in
some cases a high molecular weight (HMW) tau species
emerged. Earlier studies identified this HMW tau as a 110
kDa species produced from an alternatively spliced tran-
script of tau that is predominantly found in the peripheral
nervous system [26,27]; however the functional capacity
of HMW tau remains unclear. Another interesting finding
was the lack of detectable tau reductions in the mouse
N2A neuroblastoma cell line following treatment with
these same compounds. Human and mouse tau are proc-
essed quite distinctly, in that adult mice exclusively pro-
duce exon 10 (+) tau isoforms while normal adult
humans produce both exon 10 (+) and exon 10 (-) tau iso-
forms at a 1:1 ratio [28]. In addition, despite robust Aβ
deposition in mice transgenic for mutant forms of the
amyloid precursor protein (APP), neither tau accumula-
tion nor tangle formation has been observed in these ani-
mals. Thus, mouse tau is distinctly different from human
tau and therefore it is not surprising that compounds
affecting human tau are not capable of altering mouse tau.
It also suggests that in vivo validation of these compounds
will likely require the use of mice transgenic for human
tau or even mice that have been humanized for the MAPT
gene [29].
Conclusion
Certainly, while all of the compounds identified have
unique properties and functions, our results indicate that
microtubule disruption is a primary modifier of tau
expression and levels. While these compounds have typi-
cally been used to arrest cell division, it has yet to be deter-
mined what their impact might be in terminally
differentiated neurons that utilize microtubules and their
associated proteins in an entirely different manner from
the rest of the body. The recent study by Zhang et al. dem-
onstrated that in vivo administration of the microtubule
stabilizer  Paxceed  prevented tau sequestration and
improved axonal transport in a mouse model of tauopa-
thy, providing the first indication that compounds affect-
ing microtubule integrity might have therapeutic
potential for neurodegenerative diseases involving tau
[30]. Unfortunately tau levels were not assessed in the
mice transgenic for human tau in this study; however,
based on our findings here it would be predicted that tau
levels were reduced in those mice. Thus, in patients
already suffering from heritable dementia associated with
mutations within the MAPT gene, perhaps reducing the
available pool of the pathogenic substrate could hold
immediate clinical promise, particularly as many of the
compounds identified in this analysis are FDA-approved
and currently being used by physicians to treat other vari-
ous disorders.
Materials and methods
Cell culture and drug treatments
The human H4 neuroglioma, human BE(2)-M17 neurob-
lastoma (M17) and mouse Neuro2a (N2A) neuroblast-
oma cell lines were maintained in T-75 flasks with Opti-
MEM (Invitrogen) with 10% FBS and antibiotic. N2A cells
were supplemented with 2 mM glutamine. New cultures
were started monthly and passaged thereafter twice
weekly with trypsin. In preparation for drug treatment
and In-Cell Western analysis, H4 cells were passaged into
96-well clear bottom plates (BD Falcon) at a density of 8
× 104  cells/well and incubated overnight. Cells were
treated in triplicate for 24 hours with a single concentra-
tion (normally 1–10 μM) of each compound from the
Prestwick (880 compounds) library or vehicle (DMSO).
Based on our previous studies, EC82 (Conforma Thera-
peutics) [9] was added to each plate for use as a positive
control for tau reductions. For dose response studies, 100,
10, 1, 0.1 and 0.01 μM concentrations of drug were added
to wells in duplicate for 24 hours. For preparation of
homogenates for normal Western blot analyses, cells were
passaged into 6-well plates, incubated overnight and
treated the next day with drug or vehicle at indicated con-
centrations. Cells were then incubated for 24 hours and
harvested in lysis buffer containing (50 mM Tris-HCl pH
7.4, 1 M NaCL, 0.1% Triton-X, 5 mM EDTA) plus 1% SDS,
PMSF, and both a protease and phosphatase inhibitor
cocktail.
Western blot analysis
Cell lysates were sonicated and protein concentrations
were measured by a standard BCA assay (Pierce). The sam-
ples were then heated in Laemmli's buffer and equal
amounts of protein were loaded into 12-well 10% Tris-
HCl gels (Bio-Rad). Protein expression was then analyzed
by Western blot using anti-human tau (1:2000; DAKO),
anti-MAP2 (1:1000; Cell Signaling) and anti-GAPDH
(1:2000; BioDesign) antibodies. HRP-conjugated second-
ary antibodies were applied and visualized by ECL treat-
ment and exposure to film.
In-Cell Western blotting and quantitation
In-Cell Western analysis was performed as previously
described [8,9]. Briefly, 50 μl of media from the 96-well
plates were removed for LDH analysis to detect toxicity
(Cytotox 96 Assay Kit, Promega) and the remaining media
was aspirated. Cells were fixed with 3.7% formaldehyde
in PBS for 20 minutes and then permeabilized with three
10 minute washes in PBS + 0.1% Triton-X 100 (BioTek
Instruments Inc.). A proprietary lipid-based blocking
buffer (LBB; Li-Cor) was added for two hours, followed by
overnight incubation with rabbit anti-human tau (1:500;
DAKO) and mouse anti-human glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH; 1:1500; BioDesign) anti-
bodies in a 1:1 buffer of LBB and PBS + 0.2% Tween20.Molecular Neurodegeneration 2006, 1:6 http://www.molecularneurodegeneration.com/content/1/1/6
Page 8 of 9
(page number not for citation purposes)
After three 10 minute washes in PBS + 0.1% Tween-20,
secondary detection was carried out using two infrared
fluorescent dye conjugated antibodies in 1:1 buffer of LBB
and PBS + 0.4% Tween20; one absorbing at 680 nm (Alex-
aFluor 680; Molecular Probes) and the other absorbing at
800 nm (IRDye 800 CW; Rockland). After an hour incu-
bation and washing, the targets were simultaneously visu-
alized using the Odyssey Infrared Imaging Scanner (Li-
Cor, Lincoln, NB). Relative fluorescent units for drug-
treated samples were divided by vehicle controls to deter-
mine percent change in expression of both tau and
GAPDH levels relative to control. The student t-test was
used to determine significant toxicity effects due to drug
treatment based on the expression levels of GAPDH, and
then a separate student t-test was used to determine signif-
icant differences between tau and GAPDH levels in treated
cells.
qRT-PCR
RNA was isolated from cells and analyzed by qRT-PCR as
previously described [10,11]. Briefly, Total RNA from H4
cells treated at 3 different concentrations (10 mg/ml, 1
mg/ml and 0.1 mg/ml) in duplicate was isolated using the
RNeasy 96 technology from Qiagen and reverse tran-
scribed with MMLV reverse transcriptase and 1 M Betaine.
A standard curve was established within the reverse tran-
scription reaction by adding total RNA (template) from
untreated H4 cells covering 3 logs. 5 ng of total RNA from
all samples were added to individual wells within the
reverse transcription reaction for comparison to the stand-
ard curve. Primers for SYBR green qPCR analysis of 28S
rRNA levels and both GAPDH and Total Tau mRNA levels
were generated as previously described [10]. Experimental
wells containing 25 μl PCR reactions were run in 384-well
plates. PCR was run on the ABI 7900 as follows; 1 cycle of
95°C for 15 minutes followed by 40 cycles of 95°C for 15
seconds and 60–65°C for 1 minute. None of the primer
pairs demonstrated more than 1 peak of fluorescence
from melt curve analysis. The standard curve was calcu-
lated by plotting the threshold cycle (Ct) against the log
nanogram quantity of RNA added to the RT reactions. A
linear regression was performed and the slope, relating Ct
to log ng RNA, was calculated, and converted to a mass
quantity of standard RNA. These mass values for the genes
of interest were then normalized to 28S ribosomal RNA
mass values and then divided by GAPDH mRNA to deter-
mine fold-change in mRNA expression relative to the
standard RNA pool. These fold change values for samples
in the vehicle treated vs. drug treated were analyzed for
significance using Student t-test.
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